2–10x
Bioavailability Delta
Observed uplift range for optimized delivery vs. standard forms
Technology Stack · Enterprise Delivery Intelligence
Delivery Technology for Brands That Need Proof, Not Promises.
Liposomal systems, nano-micellization, enteric pathways, and analytical release are valuable only when they survive scale. We architect reproducible delivery performance under enterprise-grade governance.
20–200nm
Nano-Micelle Window
Engineered particle band for hydrophobic compound dispersibility
HPLC/GC-MS
Analytical Release
Every batch released by instrument-verified concentration profile
Cpk > 1.33
Scale Reliability
Process capability standard for enterprise transfer confidence
The Velvet Rope
Selective Admission for High-Impact Technology Mandates.
We only admit programs where technology choices can be validated, transferred, and defended. Selectivity protects outcomes for serious operators and eliminates low-discipline execution risk.
- You need a defensible delivery-system moat, not generic formulation mimicry.
- You require board-level technical evidence for valuation, clinic trust, or strategic exit.
- Your team is ready for disciplined validation, analytical release, and compliance governance.
- You are prepared to enter through Initiate R&D Due Diligence (paid).
Technology Protocol
Delivery Performance Must Survive Manufacturing Physics.
Our protocol aligns molecular strategy with production reality. We engineer systems for measurable absorption logic, analytical certainty, and repeatable output under industrial constraints.
Liposomal Track
Phospholipid architecture calibrated by compound behavior
Nano-Micellar Track
20–200nm dispersions for hydrophobic payload transport
Enteric Track
pH-targeted release strategy for acid-sensitive systems
Release Governance
HPLC/GC-MS release discipline with transfer-ready records
Admission Outcomes
What Qualified Technology Admission Delivers.
-
A delivery-system decision tree anchored in evidence and manufacturability.
-
Analytical and process controls prepared for QA, regulator, and investor scrutiny.
-
A transferable, enterprise-ready execution route for strategic scale-up.
Execution Ladder
Four Moves from Delivery Thesis to Enterprise Reliability.
01
Technical Diligence
Molecular and delivery-route triage with go/no-go decision logic.
02
Architecture Design
Delivery-system and process controls designed for repeatable output.
03
Validation Runs
Analytical and process verification before high-volume campaign activation.
04
Scale Transfer
Industrial execution with traceable governance and transfer-ready records.
Final Gate
Initiate R&D Due Diligence.
If your objective is category-defining delivery performance with defensible evidence, we can evaluate fit. If your objective is generic quote shopping, admission is intentionally closed.
Trust metrics: 2–10x bioavailability | 20–200nm systems | HPLC/GC-MS release | Cpk > 1.33
RELATED INTELLIGENCE
Pharmaceutical-Grade Softgel Manufacturing 3 independent rotary die lines, 100M+ capsules/month, gelatin and HPMC plant-based
EXPLORE ›
Production Formats & MOQ Reference Hard capsules 150K units, softgels 300K, sachets 250K — with finished-package counts at 30 and 60 per pack
EXPLORE ›
Physician-Formulated Supplement CDMO EBM formulations at clinical dosages with full IP ownership for doctor-led brands
EXPLORE ›
FSMP & Medical Food Formulation Clinical nutrition under EU Delegated Regulation 2016/128 for oncology and metabolic programs
EXPLORE ›
High-Volume Supplement Scale-Up PPQ validated from pilot batch to commercial production — Cpk > 1.33 process capability
EXPLORE ›
Clinical Research & Formulation Library Peer-reviewed evidence supporting our advanced delivery systems
EXPLORE ›
Science-First Manifesto — Evidence-Based Formulation Doctrine The founding principle behind our HPLC/GC-MS verified, AI-screened technology stack
EXPLORE ›
Frequently Asked Questions
Why gate technology projects with paid due diligence?
Because advanced delivery work is execution-critical. We evaluate molecular fit, process risk, and validation feasibility before admission. Paid diligence filters speculative briefs and protects active partner programs.
What is assessed in the technology admission phase?
We assess ingredient physicochemistry, delivery-system compatibility, interaction risk, analytical strategy, and industrial transfer constraints. The outcome is a go/no-go decision with technical route definition.
Do you support liposomal, nano-micellar, and enteric pathways in one program?
Yes, if justified by evidence and manufacturability. We combine or sequence delivery strategies only when absorption, stability, and production controls support enterprise reproducibility.
How do you prevent over-promising in bioavailability claims?
We use analytical and formulation evidence boundaries. Claims are framed from measurable outputs, not marketing assumptions. Programs without defensible data are not admitted to production route design.
Can enterprise auditors review your technology controls?
Yes. Qualified teams can review laboratory controls, method validation logic, CAPA governance, and transfer-readiness architecture in Gdynia. Institutional trust requires auditable systems.
Who owns the resulting formulation intelligence?
The client does under contract-defined transfer principles. We operate with zero-conflict governance and document handover suitable for continuity, diligence, and strategic transactions.
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ bears full and sole responsibility for all regulatory compliance, health claim authorization (including EFSA Article 13/14 claim dossiers and U.S. FDA notifications), labeling, and marketing of their finished product in their target market(s). Olympia Biosciences™ provides manufacturing, formulation, and analytical services only.